GlobeNewswire

TeraRecon Debuts Next Generation Northstar(TM) AI Explorer at SIIM18

Dela

National Harbor, Maryland - May 31st, 2018, May 31, 2018 (GLOBE NEWSWIRE) -- TeraRecon (www.terarecon.com) today announced that its first-of-kind Northstar(TM) AI Explorer has reached a new milestone that allows physicians to interact with individual measurements, markings, and findings created by AI image processing algorithms. To demonstrate the potential of these AI-assisted workflows, the company is previewing an end-to-end cardiac MR analysis workflow in partnership with EnvoyAI (www.envoyai.com) and Corstem (www.corstem.ai) that provides highly automated results while keeping the physician informed and in control. The new Northstar features are the latest in a rapid progression of technological achievements made as the product evolves from a results viewer to a more powerful and integrated AI interaction and observation portal.

The new Northstar AI Explorer(TM) provides the ability to not only accept or reject certain images and reports created by AI, as Northstar has done previously, but now empowers physicians to fine-tune findings and interrogate the clinical assumptions that underlie the results in AI-generated reports. The system is composed of a web-based user interface that works seamlessly alongside or within the physicians' current PACS, EMR, and enterprise viewing systems.

The Northstar AI Explorer and the EnvoyAI platform together form an application framework upon which any 3rd party algorithm developer can build. "TeraRecon strives to make AI-assisted medical imaging interpretations more accessible to physicians by offering an unprecedented level of transparency into AI functionality along with deep integrations into existing workflows that optimize ease of use and efficiency. By exposing the key clinical assumptions that these AI machines are making and stopping to collect physician feedback before proceeding, we reduce risk while accelerating innovation and clinical adoption", said Jeff Sorenson, President and CEO of TeraRecon.

The cardiac MR analysis workflow prototype is composed of Corstem AI-generated anatomic contours and clinical assumptions being quickly verified or adjusted.  The physician feedback is sent to the Corstem application hosted on the EnvoyAI platform. The workflow then completes the cardiac function and fully quantitative pixel-wise perfusion analyses, marks updated findings in the images, and generates the report. The physician can make further adjustments and send the results to the permanent archive, such as the PACS or VNA.

"The most exciting aspect of the Northstar AI Explorer is that physicians can appreciate the quality of the AI findings", said Pascal Labrecque, Chief Operating Officer of Corstem. Pascal continued, "Our proprietary deep learning algorithm performs cardiac MR contouring with some of the most sophisticated motion correction technology available. The combination of TeraRecon's Northstar AI Explorer and the EnvoyAI platform allows cutting-edge AI technology to really shine."

The trained AI algorithms are not continuously learning from physician feedback in real-time, to ensure that tight version-control and testing regimens are maintained. However, with permission and appropriate data sharing protocols from the healthcare institution, their anonymized image data and physician ground truthing feedback may be shared and used by the algorithm developer to make improved versions.

Northstar was installed at its first beta-release customer site this month, Wake Radiology (www.wakerad.com) in Raleigh, North Carolina. "My expectation is that the Northstar viewer is going to simplify the experience for my radiologists. The output from these AI algorithms are expected to far surpass what we could generate individually on any given day, for specific reports. Volumetric measurements and serial comparisons that could not be done or would take a lot of time to do individually should be automated with AI", said Dr. William Way, Chief Medical Officer of Wake Radiology.  Dr. Way continued, "Having these results readily available and nicely integrated into our PACS and reporting workflows is vastly superior to what we are doing now."

"AI is important to where we are going as a radiology provider, and it is nice to be on the cutting edge", said Matt Dewey, Chief Information Officer of Wake Radiology.  Matt continued, "Because algorithms work differently and each of them has different inputs and outputs, my radiologists would otherwise have to have a different way of working with each one.  Northstar solves this problem by providing a simple and consistent way that our physicians work with the output of algorithms from many sources, and adapting itself to their personal preferences."

TeraRecon AI solutions will be demonstrated during the Society for Imaging Informatics in Medicine annual meeting, May 31st through June 2nd in National Harbor, Maryland at Booth #405. Online demonstrations and more information are available by contacting TeraRecon at info@terarecon.com.

About TeraRecon (www.terarecon.com) TeraRecon is a leader in advanced visualization, image viewing, and post-processing. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry's leading independent technology analyst. We are committed to redefining advanced visualization by leveraging artificial intelligence, and to improving radiology workflow through personalized automation features that increase efficiency.

About EnvoyAI (www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor-neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians. 

About Wake Radiology ( www.wakerad.com Founded in 1953, Wake Radiology is the leading provider of outpatient medical imaging in Central North Carolina. Its physicians have been trained as experts in specific imaging specialties - ranging from breast cancer detection and pediatrics to sports medicine and neuroradiology - to accurately diagnose healthcare issues. Another hallmark of Wake Radiology is its commitment to low-dose imaging and the elimination of unnecessary or duplicate exams. This approach strives to improve patient outcomes and reduces the overall cost of healthcare. Wake Radiology is the region's largest outpatient imaging practice with nearly 50 radiologists who perform close to 600,000 procedures each year. It is the first outpatient imaging provider in the Triangle to earn the American College of Radiology's prestigious Breast Imaging Center of Excellence designation. Wake Radiology is an independent, locally owned and physician-led practice that actively supports the local community.

About CorStem (www.corstem.ai) Corstem is a machine learning and artificial intelligence software developer specialized in medical imaging analysis and computer vision. Founded in 2016, its AI-powered tools are setting the standard in dynamic cardiac analysis. Corstem enables a whole new level of efficiency and automation for diagnosis aid to save valuable physician and patient time. 

IMPORTANT REGULATORY NOTICE: The TeraRecon Northstar and Corstem cardiac MR products mentioned herein are not for clinical use or sale at this time.

Press Inquiries US: 1-650-372-1100 | info@terarecon.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TeraRecon, Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum